Jun 14, 2022 7:00 am EDT Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
May 27, 2022 7:00 am EDT Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
May 25, 2022 5:00 pm EDT Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
May 24, 2022 5:00 pm EDT TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
May 20, 2022 7:00 am EDT Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
May 19, 2022 7:00 am EDT Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
May 10, 2022 7:00 am EDT Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
